Piper and Hoen et al.1 utilized a high-affinity anti-PD-1 antibody fused to an IL-2 variant (IL2v) that no longer binds IL-2Rα while still stimulating tumor antigen-specific T cell expansion and differentiation to “better effectors”. This evidence concerns the gene IL2 and neoplasm.